Can the pharmaceutical industry reduce attrition rates? (original) (raw)
- Opinion
- Published: 01 August 2004
Nature Reviews Drug Discovery volume 3, pages 711–716 (2004)Cite this article
- 38k Accesses
- 3023 Citations
- 185 Altmetric
- Metrics details
Abstract
The pharmaceutical industry faces considerable challenges, both politically and fiscally. Politically, governments around the world are trying to contain costs and, as health care budgets constitute a very significant part of governmental spending, these costs are the subject of intense scrutiny. In the United States, drug costs are also the subject of intense political discourse. This article deals with the fiscal pressures that face the industry from the perspective of R&D. What impinges on productivity? How can we improve current reduced R&D productivity?
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Additional access options:
Similar content being viewed by others
References
- Kola, I. & Rafferty, M. New technologies that may impact drug discovery in the 5–10 year timeframe workshop. 2002 Biomed. Expo Ann Arbor Michigan (data derived from Prous Science, Drugs News Prospect (2002).
- Franz, S. 2003 approvals: a year of innovation and upward trends. Nature Rev. Drug Discov. 3, 103–105 (2004).
Article Google Scholar - Accenture Consulting. High performance drug discovery: an operating model for a new era. Accenture (2001).
- DiMasi, J. A., Hansen, R. W. & Grabowski, H. G. The price of innovation: new estimates of drug development costs. J. Health Econ. 22, 151–185 (2003).
Article Google Scholar - Fearn, C. J. IMS Health. The World Pharmaceutical Market Presented at the Strategic Management Review, Australia, 19–20 June (2002).
Google Scholar - Booth, B., Glassman, R. & Ma, P. Oncology's trials. Nature Rev. Drug Discov. 2, 609–610 (2003).
Article CAS Google Scholar - Benjamin, G. A. & Lumley, C. E. Industry Success Rates 2003 Including Trends in Success Rates CMR Report Number 03–202 R (CMR International Surrey, UK, 2003).
Google Scholar - Van den Haak, M. A., Palachandran, J. & Benjamin, G. A. Performance Metrics in Global Pharmaceutical R&D, Company specific review 2002 for Merck & Co. (CMR International, Surrey, UK, 2003).
Google Scholar - Roberds, S. L. et al. BACE knockout mice are healthy despite lacking the primary β-secretase activity in brain: implications for Alzheimer's disease therapeutics. Hum. Mol. Genet. 10, 1317–1324 (2001).
Article CAS Google Scholar - Gowen, et al. Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J. Bone Miner. Res. 14, 1654–1663 (1999).
Article CAS Google Scholar - Lazner, F., Gowen, M. & Kola, I. An animal model for pycnodysostosis: the role of cathepsin K in bone remodeling. Mol. Med. Today 5, 413–414 (1999).
Article CAS Google Scholar - Ma, P. & Zemmel, R. Value of novelty? Nature Rev. Drug Discov. 1, 571–572 (2002).
Article CAS Google Scholar
Acknowledgements
We wish to acknowledge Datamonitor for the assembly of data (Pharmaceutical R&D Benchmarking Forum) used in this study.
Author information
Authors and Affiliations
- Senior Vice-President of Basic Research at Merck Research Labs, 126 East Lincoln Avenue, Rahway, 07075, New Jersey, USA
Ismail Kola Ph.D. (Med) - Senior Vice-President, Pharmaceutical Sciences and Compliance Clinical Sciences at Schering-Plough Research Institute, 2000 Galloping Hill Road, Kenilworth, 07033, New Jersey, USA
John Landis Ph.D.
Authors
- Ismail Kola Ph.D. (Med)
You can also search for this author inPubMed Google Scholar - John Landis Ph.D.
You can also search for this author inPubMed Google Scholar
Corresponding author
Correspondence toIsmail Kola Ph.D. (Med).
Ethics declarations
Competing interests
I.K. is an employee of Merck & Co., Inc., and has financial interests in Merck, Pfizer Inc. and Schering-Plough Corp. J.L. is an employee of Schering-Plough Corp. and has financial interests in Schering-Plough and Pfizer Inc.
Related links
Related links
FURTHER INFORMATION
Rights and permissions
About this article
Cite this article
Kola, I., Landis, J. Can the pharmaceutical industry reduce attrition rates?.Nat Rev Drug Discov 3, 711–716 (2004). https://doi.org/10.1038/nrd1470
- Issue Date: 01 August 2004
- DOI: https://doi.org/10.1038/nrd1470